argenx to Present at TD Cowen 46th Annual Healthcare Conference

Core Viewpoint - argenx is actively engaging in the healthcare sector by participating in conferences to discuss advancements in immunology and its commitment to treating severe autoimmune diseases [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, exploring its potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]. Event Participation - Karen Massey, the Chief Operating Officer of argenx, will participate in a fireside chat at the TD Cowen 46 Annual Healthcare Conference on March 2 at 11:50 a.m. ET [1]. - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2].